Try our beta test site

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by New York Presbyterian Hospital.
Recruitment status was:  Recruiting
Information provided by:
New York Presbyterian Hospital Identifier:
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.

Condition Intervention Phase
Cervical Dysplasia
Drug: diindolylmethane (DIM)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN)

Resource links provided by NLM:

Further study details as provided by New York Presbyterian Hospital:

Primary Outcome Measures:
  • To determine if oral DIM is effective in promoting the regression of CIN in women

Secondary Outcome Measures:
  • To correlate the response to DIM with HPV colonization
  • To assess for any adverse effects of oral DIM in women

Estimated Enrollment: 62
Study Start Date: September 2000
Estimated Study Completion Date: August 2005
Detailed Description:
To determine if the use of oral Diindolylmethane (DIM), a marketed cruciferous vegetable based dietary supplement (BioResponse-DIM®), is associated with the regression of cervical dysplasia in otherwise healthy women. Additionally, the study aims to see how the use of the BioResponse-DIM supplement correlates with cervical HPV colonization, and to asses the tolerability of daily DIM supplementation

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Non pregnant women greater than or equal to 18 years of age able to consent
  • CIN II or III confirmed by histology
  • Karnofsky performance status >= 80
  • No prior treatment for dysplasia in the past 4 months

Exclusion Criteria:

  • Incompletely visible lesion
  • Diethylstilbestrol (DES) exposure
  • HIV seropositive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00212381

Contact: Roopa R Chakkappan, M.P.H 212-312-5268

United States, New York
NYU School of Medicine Recruiting
New York, New York, United States, 10016
Contact: Alan Arslan, M.D.    212-263-7792   
Contact: Giuseppe Del Priore, M.D, M.P.H.    212-312-5268   
Sponsors and Collaborators
New York Presbyterian Hospital
Study Director: Giuseppe Del Priore, M.D., M.P.H. NY Downtown Hospital
Principal Investigator: Alan Arslan, M.D. NYU School of Medicine
  More Information Identifier: NCT00212381     History of Changes
Obsolete Identifiers: NCT00206804
Other Study ID Numbers: 9218
Study First Received: September 13, 2005
Last Updated: September 13, 2005

Keywords provided by New York Presbyterian Hospital:
cervical dysplasia, diindolylmethane, pap smear

Additional relevant MeSH terms:
Cervical Intraepithelial Neoplasia
Uterine Cervical Dysplasia
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Precancerous Conditions
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female processed this record on March 24, 2017